Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.
about
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection.
P2860
Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Infections in patients taking ...... ancies: two-year cohort study.
@ast
Infections in patients taking ...... ancies: two-year cohort study.
@en
Infections in patients taking ...... ancies: two-year cohort study.
@nl
type
label
Infections in patients taking ...... ancies: two-year cohort study.
@ast
Infections in patients taking ...... ancies: two-year cohort study.
@en
Infections in patients taking ...... ancies: two-year cohort study.
@nl
prefLabel
Infections in patients taking ...... ancies: two-year cohort study.
@ast
Infections in patients taking ...... ancies: two-year cohort study.
@en
Infections in patients taking ...... ancies: two-year cohort study.
@nl
P2093
P2860
P356
P1476
Infections in patients taking ...... ancies: two-year cohort study.
@en
P2093
Aoife C Molloy
Archibald G Prentice
Christopher C Kibbler
P2860
P2888
P356
10.1186/1471-2334-13-317
P577
2013-07-12T00:00:00Z
P5875
P6179
1051958596